Supreme Court Hears Wyeth v. Levine Drug Pre-Emption Case
This article was originally published in The Gray Sheet
Executive Summary
U.S. Supreme Court justices focused their questioning during Nov. 3 oral arguments in the case of Wyeth v. Levine on the specific risk-benefit trade-off for the drug in question, but also addressed broader principles of FDA policy
You may also be interested in...
Wyeth Supreme Court Case Could Have Impact On Device Suits, Lawyers Say
If the Supreme Court favors "implied" federal pre-emption for FDA-approved pharmaceutical labeling in a case that will be heard by the court next month, some devices may receive additional protections too, lawyers suggest
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.